Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma

by NASDAQ Market News April 27, 2020

NASDAQ Market News
Click here to email author

Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients

Saniona is Inviting Investors to Participate to a Presentation of the Positive Topline Results from the Phase 2 Trial: Tesomet for the Treatment of Hypothalamic Obesity

Ads